Carrier Screening Trends And Competitive Analysis

Report Overview

The carrier screening market is experiencing significant growth, driven by the rising incidence of genetic disorders such as cystic fibrosis, sickle cell disease (SCD), and Tay-Sachs disease. There are nearly 10,000 known single-gene disorders, also called monogenic disorders, resulting from mutations in a single gene. According to the World Health Organization, approximately 10 in every 1,000 individuals are affected, meaning an estimated 70–80 million people worldwide live with such conditions. In the U.S., SCD affects over 100,000 individuals, with particularly high prevalence among people of African American descent.

Cystic fibrosis, another inherited disorder, occurs in roughly one in 2,500–3,500 White Americans and poses lifelong healthcare challenges. Hemophilia, primarily affecting males, further contributes to the disease burden, with over 30,000 men living with the condition in the U.S. Hemophilia A occurs in approximately one in 5,617 male births, while hemophilia B is seen in about one in 19,283 male births. The widespread prevalence of these conditions underscores the critical need for effective genetic screening solutions.

The U.S. Orphan Drug Act defines rare diseases as those affecting fewer than 200,000 people, with a prevalence of about one in 1,900 individuals. Around 80% of these rare diseases are genetic, collectively impacting nearly 2% of the population. While individually uncommon, such disorders often lead to higher hospitalization rates and increased healthcare costs. Early and accurate diagnosis can therefore improve patient outcomes while reducing financial burdens on families.

Advances in biotechnology, including molecular diagnostics and sequencing technologies, have improved detection capabilities, though clinical evaluation and detailed medical histories remain essential, particularly in cases involving multiple genetic disorders (MGD). Dual or overlapping genetic diagnoses complicate assessments, with MGD prevalence ranging from 0.4% to 8.5% in exome sequencing cohorts. The U.S.-based Undiagnosed Diseases Network (UDN) plays a pivotal role in addressing complex and elusive cases through genomic approaches and collaborative research, advancing our understanding of undiagnosed and multi-gene conditions.

Technological progress, particularly in next-generation sequencing (NGS) and bioinformatics, has transformed the carrier screening market by enhancing accuracy, speed, and cost-efficiency. Traditional genetic tests typically targeted a limited number of conditions in high-risk populations. Modern NGS-based panels, however, can simultaneously screen hundreds of mutations, offering a far more comprehensive assessment.

Targeted genotyping panels represented an early advancement, enabling simultaneous screening of multiple known variants, as seen in cystic fibrosis testing, though they were limited to previously identified mutations. The emergence of NGS allowed sequencing of dozens or hundreds of genes in a single run, expanding carrier screening panels significantly. Challenges remain, as traditional short-read NGS can struggle with complex genomic regions such as repeat expansions, structural variants, methylation patterns, and high-homology genes. To address these limitations, innovations like highly accurate long-read sequencing, including HiFi technologies, are emerging. For instance, in September 2025, PacBio launched its expanded PureTarget portfolio for high-throughput carrier screening, leveraging HiFi sequencing to consolidate multiple assays into a single scalable test, allowing precise analysis of challenging genes.

The global shift toward personalized medicine is also fueling demand for carrier screening. Individuals and couples are increasingly proactive in managing reproductive health, seeking genetic counseling alongside screening. This trend reflects growing awareness that carrier status directly impacts family planning, pregnancy outcomes, and the health of future generations.

Historical carrier screening programs highlight the impact of awareness on health outcomes. Early initiatives, such as Tay-Sachs disease screening in Ashkenazi Jewish communities, showed how education and testing could significantly reduce disease prevalence. Similarly, community-driven sickle cell screening programs in African American populations demonstrated the importance of proactive engagement, though subsequent government-led efforts revealed the risks of inadequate implementation and misinformation. These lessons underscore the move toward personalized medicine, where individuals and communities actively seek genetic insights to make informed healthcare and reproductive decisions.

In Turkey, Spinal Muscular Atrophy (SMA), caused by variants in the SMN1 gene, affects 1–3 per 10,000 births, with a carrier frequency of 1 in 50. The 2021 SMA Carrier Screening Program in Turkey highlighted strong awareness among healthcare professionals, while also revealing knowledge gaps and emphasizing the need for enhanced education and awareness initiatives.

Carrier Screening Pipeline Prospects and Future Outlook

Market Trends

Key Drivers, Trends, and Market Insights in the Global Carrier Screening Industry

Traditional tests limited to a few conditions; NGS panels can screen hundreds of mutations simultaneouslyKey Strategic Activities undertaken by major players

Product Benchmarking

Recent Developments

2025

Myriad Genetics (June 2025)

Launched early access to the FirstGene Multiple Prenatal Screen and initiated a large-scale clinical study (over 5,000 patients via the CONNECTOR study) to both provide patient reports and generate evidence for the test’s validity and utility.

CENTOGENE (May 2025)

Introduced a new Reproductive Genetics Portfolio, including Preimplantation Genetic Testing for Aneuploidy (PGT-A) and comprehensive carrier screening services (CentoScreen). PGT-A leverages CENTOGENE’s database of over one million sequences for high sensitivity and accuracy, with an optional rapid 24-hour turnaround for IVF embryos. CentoScreen covers ≥99% of 332 genes for individuals or couples, enabling early detection of inherited genetic risks.

BillionToOne, Inc. (May 2025)

Expanded their UNITY Fetal Risk Screen to include 14 genes (recessive and X-linked conditions) plus aneuploidies, allowing fetal risk assessment as early as nine weeks of pregnancy using a single maternal sample. The new panel adds nine actionable conditions beyond the original five recommended by ACOG.

BillionToOne, Inc. (June 2025)

Published results from a large retrospective study (over 100,000 general-risk pregnancies) showing that the UNITY Fetal Risk Screen reliably identifies fetuses at high risk for cystic fibrosis (CF).

2024

UAE Ministry of Health and Prevention (December 2024)

Announced that starting January 2025, genetic testing will become mandatory in the national premarital screening program for all Emiratis planning to marry. Screening will expand to 570 genes associated with over 840 genetic disorders, aiming to reduce inherited disease incidence and strengthen the nation’s genome strategy.

BGI Genomics (March 2024)

Released the NOVA Newborn Genetic Screening Test, assessing risk across 246 genes and 112 genetic diseases (covering 254 subtypes). This advances newborn screening using prenatal carrier screening approaches.

KK Women’s & Children’s Hospital, Singapore (September 2024)

Launched PREDICT (PaREnthood genetic DIsease Carrier Test), the first expanded screening program in Asia targeting “at-risk” couples for severe recessive genetic disorders. The voluntary, free program (2024–2027) targets ~40,000 eligible couples, focusing on early reproductive planning.

Regulatory Scenario

North America

In North America, carrier screening is primarily regulated under general medical device and laboratory oversight. In the United States, the Food and Drug Administration (FDA) regulates genetic tests marketed as in vitro diagnostics, focusing on safety, efficacy, and labeling. However, many carrier screening tests are offered as laboratory-developed tests (LDTs), which fall under CLIA (Clinical Laboratory Improvement Amendments) oversight rather than direct FDA pre-market approval. The Centers for Medicare & Medicaid Services (CMS) ensures laboratory quality standards, while professional guidelines from the American College of Medical Genetics and Genomics (ACMG) and NSGC guide clinical use. In Canada, regulation is primarily provincial, with Health Canada overseeing medical devices, and laboratories adhering to accreditation standards, such as ISO 15189, ensuring reliable carrier testing results.

Europe

European regulatory oversight is guided by the In Vitro Diagnostic Regulation (IVDR 2017/746), which came into full effect in May 2022. IVDR requires genetic tests, including carrier screening panels, to undergo strict conformity assessments, risk classification, and clinical evidence demonstration before market access. Individual countries may also have additional requirements; for example, in Germany, genetic testing is regulated under the Genetic Diagnostics Act (GenDG), mandating genetic counseling before testing. Many European nations emphasize pre-test counseling, informed consent, and ethical oversight due to concerns about reproductive decision-making.

Asia Pacific

Regulatory frameworks in the Asia Pacific vary widely, reflecting diverse healthcare systems. In Japan, carrier and prenatal genetic tests are regulated under the Pharmaceutical and Medical Device Act (PMD Act), requiring approvals for clinical validity and safety. Singapore and South Korea enforce stringent clinical validation and licensing for laboratories offering genetic tests. Emerging markets like China and India are still formalizing carrier screening regulations; however, the National Health Commission (China) and the Indian Council of Medical Research (ICMR) provide guidelines to ensure test accuracy and ethical practice. Across the region, carrier screening adoption is often tied to public health initiatives and reproductive counseling.

Latin America

In Latin America, carrier screening regulation is fragmented. Countries like Brazil and Mexico regulate genetic tests under national health authorities (e.g., ANVISA in Brazil) with requirements for laboratory certification, clinical validation, and medical supervision. Many other countries rely on professional medical societies for guidance. Ethical oversight, informed consent, and counseling are emphasized due to the sensitive nature of reproductive genetic testing. While private-sector testing is growing, widespread adoption is sometimes limited by cost and access to certified laboratories.

Middle East

The Middle East has witnessed significant government-led initiatives in carrier screening. Countries like Saudi Arabia, UAE, and Qatar have implemented mandatory or highly recommended premarital genetic testing programs. Regulations are typically enforced by national health ministries, with clear mandates for laboratory certification, genetic counseling, and reporting standards. The UAE, for instance, expanded its premarital screening to cover hundreds of genes and over 800 disorders starting 2025, reflecting the region’s strong emphasis on preventive reproductive healthcare.

Africa

Carrier screening in Africa is still emerging and largely governed by individual country policies and international laboratory standards. South Africa, for example, regulates genetic testing through the Health Professions Council of South Africa (HPCSA) and laboratory accreditation bodies like SABS/ISO 15189. Most African nations rely on a combination of clinical guidelines, laboratory accreditation, and international best practices rather than comprehensive national legislation. Public adoption is limited by awareness, infrastructure, and healthcare access, but regional initiatives are increasingly supporting carrier screening programs for prevalent inherited disorders like sickle cell disease and thalassemia.